机构:[1]Department of Respiratory Diseases, Peking University Third Hospital[2]Department of Respiratory Diseases, Beijing Tongren Hospital, Beijing, People’s Republic of China首都医科大学附属北京同仁医院首都医科大学附属同仁医院
BACKGROUND: The role of exhaled H2S as a marker of airway inflammation and its relationship with COPD severity remain to be determined. METHODS: Airway inflammation was classified in 77 COPD subjects based on the presence of inflammatory cells in induced sputum. We investigated the association between disease phenotype and exhaled H2S, lung function, and plasma levels of several inflammatory factors, including tumor necrosis factor alpha, interleukin-8, and leukotriene B-4. RESULTS: In total, 33.77% of enrolled COPD subjects were diagnosed with eosinophilia. These subjects had a longer disease course, smoked fewer cigarettes, and experienced more frequent exacerbation events before study enrollment. However, they also had worse lung function and larger residual volume, they demonstrated greater changes in FEV1, following bronchodilator inhalation. Although levels of plasma inflammatory factors did not significantly differ between subjects with and without eosinophilia, subjects without eosinophilia had significantly higher levels of exhaled H2S (9.19 +/- 2.74 vs 7.24 +/- 1.68 parts per billion, P = .01). Furthermore, exhaled H2S levels were negatively correlated with induced sputum eosinophils (r = 0.45, P = .05), and positively correlated with inspiratory capacity in COPD subjects (r = 0.51, P = .026), but did not correlate significantly with plasma inflammatory factors. A cut-off value of 7.10 parts per billion of exhaled H2S predicted a non-eosinophilic phenotype with 68.6% sensitivity and 77.9% specificity. CONCLUSIONS: Exhaled levels of H2S were lower in subjects with eosinophilia. Increased levels of exhaled H2S predicted a non-eosinophilic phenotype in our study population. (C) 2015 Daedalus Enterprises
基金:
National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81170012, 81370141]; Research Special Fund for Public Welfare Industry of Health [201002008]; Beijing Key Laboratory of Respiratory and Pulmonary Circulation Disorders grant [2013HXFB05]
第一作者机构:[1]Department of Respiratory Diseases, Peking University Third Hospital
共同第一作者:
通讯作者:
通讯机构:[1]Department of Respiratory Diseases, Peking University Third Hospital[*1]Department of Respiratory Diseases, Peking University Third Hospital, Beijing 100191, People’s Republic of China